ExcelFin Acquisition Corp.
XFINU
NASDAQ Global Market10.60
USD
-1.40
- -
ExcelFin Acquisition Corp.
XFINU
(NASDAQ Global Market)
Recent
price
10.60
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- ExcelFin Acquisition Corp. (NASDAQ:XFINU) is a blank check company whose units comprise one share of Class A common stock and one-half of one redeemable warrant, with whole warrants exercisable at $11.50 per share; it focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses, primarily targeting opportunities in FinTech, technology, media, telecommunications, and healthcare. Incorporated in Delaware in 2021 and headquartered in Fort Mill, South Carolina, with prior addresses in San Francisco, California, the company raised $200 million in its initial public offering in October 2021 through 20 million units priced at $10.00 each, underwritten by UBS Investment Bank, Exos Securities LLC, and KeyBanc Capital Markets. ExcelFin's sponsors include Grand Fortune Capital, LLC, an affiliate of an investment group experienced in significant M&A transactions and investments across its focus sectors, and Fin Venture Capital, a private equity firm specializing in FinTech software. In its most significant recent development, ExcelFin completed a reverse merger business combination with Baird Medical Investment Holdings Limited, a leading microwave ablation medical device company in China that recently expanded into the U.S. market, on October 1, 2024; the resulting entity, Baird Medical Investment Holdings Limited (PubCo), commenced trading on Nasdaq under the symbols BDMD and BDMDW on October 2, 2024, following stockholder approval at a special meeting on September 26, 2024 where approximately 99.9% of votes cast supported the transaction. Concurrent with the merger closing, founders of Baird Medical and Grand Fortune Capital subscribed to a $4,900,000 convertible preferred investment in the combined company; the deal, initially announced on June 26, 2023, involved multiple extensions, including to December 25, 2024, and advisors such as Dechert LLP for Baird Medical, Allen Overy Shearman Sterling US LLP for ExcelFin, and Cohen & Company Capital Markets as lead financial advisor. ExcelFin Acquisition Corp. operates as a subsidiary of ExcelFin SPAC LLC and maintains no significant independent operations beyond pursuing such combinations.